(ATEC) Alphatec Holdings - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.272m USD | Total Return: -34.6% in 12m

Spinal Implants, Surgical Instruments, Medical Imaging, Biologics, Robotics
Total Rating 18
Safety 28
Buy Signal -0.77
Medical Devices
Industry Rotation: +5.3
Market Cap: 1.27B
Avg Turnover: 30.9M
Risk 3d forecast
Volatility60.2%
VaR 5th Pctl9.18%
VaR vs Median-9.59%
Reward TTM
Sharpe Ratio-0.33
Rel. Str. IBD0.7
Rel. Str. Peer Group1.8
Character TTM
Beta1.287
Beta Downside2.162
Hurst Exponent0.392
Drawdowns 3y
Max DD73.51%
CAGR/Max DD-0.25
CAGR/Mean DD-0.53
EPS (Earnings per Share) EPS (Earnings per Share) of ATEC over the last years for every Quarter: "2021-03": -0.26, "2021-06": -0.39, "2021-09": -0.36, "2021-12": -0.4, "2022-03": -0.43, "2022-06": -0.36, "2022-09": -0.35, "2022-12": -0.33, "2023-03": -0.4, "2023-06": -0.43, "2023-09": -0.35, "2023-12": -0.37, "2024-03": -0.34, "2024-06": -0.29, "2024-09": -0.28, "2024-12": -0.0638, "2025-03": -0.0879, "2025-06": 0.02, "2025-09": 0.03, "2025-12": 0.06, "2026-03": -0.2201,
Last SUE: -4.00
Qual. Beats: -1
Revenue Revenue of ATEC over the last years for every Quarter: 2021-03: 44.121, 2021-06: 62.249, 2021-09: 62.88, 2021-12: 73.962, 2022-03: 70.933, 2022-06: 84.151, 2022-09: 89.839, 2022-12: 105.944, 2023-03: 109.11, 2023-06: 116.92, 2023-09: 118.262, 2023-12: 137.97, 2024-03: 138.477, 2024-06: 145.573, 2024-09: 150.719, 2024-12: 176.793, 2025-03: 169.18, 2025-06: 185.544, 2025-09: 196.503, 2025-12: 212.928, 2026-03: 192.108,
Rev. CAGR: 26.01%
Rev. Trend: 99.9%
Last SUE: -0.95
Qual. Beats: -1

Warnings

Interest Coverage Ratio -2.0 is critical

Altman Z'' -6.85 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

Confidence

Description: ATEC Alphatec Holdings

Alphatec Holdings, Inc. (ATEC) is a medical technology company specializing in the design and manufacture of surgical solutions for spinal disorders. The company’s portfolio integrates hardware, such as the Invictus fixation system and Sigma retractors, with a digital platform known as Alpha InformatiX. This platform includes the EOS full-body imaging system and the Valence robotic-navigation suite, aimed at improving surgical precision and patient outcomes.

The business operates within the specialized spinal surgery market, a sector characterized by high research and development costs and rigorous regulatory requirements. Alphatec utilizes a hybrid distribution model, leveraging both direct sales representatives and independent agents to reach healthcare providers globally. In addition to hardware, the company develops biologics, including demineralized bone matrices and cellular scaffolds, to facilitate bone graft fusion during spinal procedures.

For a deeper look into the companys financial health and valuation metrics, consider reviewing the detailed analysis on ValueRay.

Headlines to Watch Out For
  • Adoption of the PTP surgical technique drives high-growth procedural volume
  • Expansion of EOS imaging and Valence robotic systems increases capital equipment revenue
  • Transition to a direct sales force improves operating margins and market share
  • High research and development spending delays path to sustained GAAP profitability
  • Strategic shift toward lateral spine procedures captures market share from legacy competitors
Piotroski VR-10 (Strict) 4.5
Net Income: -125.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 11.14 > 1.0
NWC/Revenue: 27.43% < 20% (prev 43.13%; Δ -15.70% < -1%)
CFO/TA 0.06 > 3% & CFO 51.6m > Net Income -125.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.90 > 1.5 & < 3
Outstanding Shares: last quarter (154.1m) vs 12m ago 4.99% < -2%
Gross Margin: 65.32% > 18% (prev 0.69%; Δ 6.46k% > 0.5%)
Asset Turnover: 99.32% > 50% (prev 81.77%; Δ 17.55% > 0%)
Interest Coverage Ratio: -1.97 > 6 (EBITDA TTM -1.28m / Interest Expense TTM 42.1m)
Altman Z'' -6.85
A: 0.27 (Total Current Assets 456.2m - Total Current Liabilities 240.2m) / Total Assets 799.5m
B: -1.82 (Retained Earnings -1.46b / Total Assets 799.5m)
C: -0.10 (EBIT TTM -83.1m / Avg Total Assets 792.5m)
D: -1.87 (Book Value of Equity -1.46b / Total Liabilities 781.2m)
Altman-Z'' = -6.85 = D
Beneish M -3.04
DSRI: 0.99 (Receivables 112.8m/92.8m, Revenue 787.1m/642.3m)
GMI: 1.06 (GM 65.32% / 68.96%)
AQI: 1.01 (AQ_t 0.22 / AQ_t-1 0.22)
SGI: 1.23 (Revenue 787.1m / 642.3m)
TATA: -0.22 (NI -125.4m - CFO 51.6m) / TA 799.5m)
Beneish M = -3.04 (Cap -4..+1) = AA
What is the price of ATEC shares?

As of May 27, 2026, the stock is trading at USD 8.06 with a total of 2,743,946 shares traded.
Over the past week, the price has changed by -0.37%, over one month by -22.20%, over three months by -42.47% and over the past year by -34.58%.

Is ATEC a buy, sell or hold?

Alphatec Holdings has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy ATEC.

  • StrongBuy: 4
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ATEC price?
Analysts Target Price 17.3 115%
Alphatec Holdings (ATEC) - Fundamental Data Overview as of 25 May 2026
Market Cap USD = 1.27b (1.27b USD * 1.0 USD.USD)
P/E Forward = 333.3333
P/S = 1.6159
P/B = 126.5491
P/EG = 0.4838
Revenue TTM = 787.1m USD
EBIT TTM = -83.1m USD
EBITDA TTM = -1.28m USD
Long Term Debt = 507.9m USD (from longTermDebt, last quarter)
Short Term Debt = 72.2m USD (from shortTermDebt, last quarter)
Debt = 632.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 29.6m
Net Debt = 492.8m USD (calculated: Debt 632.7m - CCE 139.9m)
Enterprise Value = 1.76b USD (1.27b + Debt 632.7m - CCE 139.9m)
Interest Coverage Ratio = -1.97 (Ebit TTM -83.1m / Interest Expense TTM 42.1m)
EV/FCF = 253.9x (Enterprise Value 1.76b / FCF TTM 6.95m)
FCF Yield = 0.39% (FCF TTM 6.95m / Enterprise Value 1.76b)
FCF Margin = 0.88% (FCF TTM 6.95m / Revenue TTM 787.1m)
Net Margin = -15.93% (Net Income TTM -125.4m / Revenue TTM 787.1m)
Gross Margin = 65.32% ((Revenue TTM 787.1m - Cost of Revenue TTM 273.0m) / Revenue TTM)
Gross Margin QoQ = 61.08% (prev 61.24%)
Tobins Q-Ratio = 2.21 (Enterprise Value 1.76b / Total Assets 799.5m)
Interest Expense / Debt = 6.65% (Interest Expense 42.1m / Debt 632.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -65.7m (EBIT -83.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.90 (Total Current Assets 456.2m / Total Current Liabilities 240.2m)
Debt / Equity = 34.66 (Debt 632.7m / totalStockholderEquity, last quarter 18.3m)
 Debt / EBITDA = -386.2 (out of range, set to none) (Net Debt 492.8m / EBITDA -1.28m)
 Debt / FCF = 70.92 (Net Debt 492.8m / FCF TTM 6.95m)
Total Stockholder Equity = 28.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.82% (Net Income -125.4m / Total Assets 799.5m)
RoE = -8.43% (Net Income TTM -125.4m / Total Stockholder Equity 1.49b)
RoCE = -4.17% (EBIT -83.1m / Capital Employed (Equity 1.49b + L.T.Debt 507.9m))
 RoIC = -13.36% (negative operating profit) (NOPAT -65.7m / Invested Capital 491.5m)
 WACC = 8.76% (E(1.27b)/V(1.90b) * Re(10.51%) + D(632.7m)/V(1.90b) * Rd(6.65%) * (1-Tc(0.21)))
Discount Rate = 10.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 6.48%
[DCF] Terminal Value 73.99% ; FCFF base≈6.95m ; Y1≈6.98m ; Y5≈7.39m
 [DCF] Fair Price = N/A (negative equity: EV 107.4m - Net Debt 492.8m = -385.4m; debt exceeds intrinsic value)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: 99.87 | Revenue CAGR: 26.01% | SUE: -0.95 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=+10.50% | Revisions=+33% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.09 | Chg30d=+13.09% | Revisions=+14% | Analysts=9
EPS current Year (2026-12-31): EPS=0.32 | Chg30d=+9.29% | Revisions=+40% | GrowthEPS=+537.7% | GrowthRev=+15.5%
EPS next Year (2027-12-31): EPS=0.58 | Chg30d=+4.61% | Revisions=-27% | GrowthEPS=+80.6% | GrowthRev=+16.6%
[Analyst] Revisions Ratio: +40%